NCT03717415View on ClinicalTrials.gov

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

November 1, 2022

Conditions
Locally Advanced or Metastatic Solid Tumor
Interventions
DRUG

Rebastinib

Administered orally

DRUG

Carboplatin

Administered by IV infusion

Trial Locations (9)

28204

Levine Cancer Institute, Charlotte

37203

Sarah Cannon Research Institute, Nashville

43210

The Ohio State University, Columbus

60637

University of Chicago, Chicago

66160

University of Kansas Medical Center, Kansas City

77030

MD Anderson Cancer Center, Houston

78240

NEXT Oncology, San Antonio

90404

UCLA Medical Center, Santa Monica

94115

University of California San Francisco (UCSF), San Francisco

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY